| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Investor presentation |
| 08/09/2023 |
8-K
| Investor presentation, Quarterly results |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/29/2023 |
4
| Carlo Rizzuto (Director) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Granted 44,000 options to buy
@ $3.19, valued at
$140.4k
|
|
| 06/29/2023 |
4
| Riva Alessandro (Director) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Granted 44,000 options to buy
@ $3.19, valued at
$140.4k
|
|
| 06/29/2023 |
4
| JIMENEZ JOSEPH (Director) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Granted 44,000 options to buy
@ $3.19, valued at
$140.4k
|
|
| 06/29/2023 |
4
| BUTITTA CYNTHIA M (Director) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Granted 44,000 options to buy
@ $3.19, valued at
$140.4k
|
|
| 06/29/2023 |
4
| Blackwell Kimberly (Director) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Granted 44,000 options to buy
@ $3.19, valued at
$140.4k
|
|
| 06/29/2023 |
4
| Quimi Daphne (Director) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Granted 44,000 options to buy
@ $3.19, valued at
$140.4k
|
|
| 06/29/2023 |
4
| Walbert Timothy P (Director) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Granted 44,000 options to buy
@ $3.19, valued at
$140.4k
|
|
| 06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/17/2023 |
4
| Carr Douglas (SVP Finance & Operations) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Granted 120,846 shares
@ $0 |
|
| 05/17/2023 |
4
| Diem Michael Craig (CFO) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Granted 151,058 shares
@ $0 |
|
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
8-K/A
| Quarterly results |
| 05/05/2023 |
8-K
| Quarterly results |
| 04/17/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/05/2023 |
4
| Borges Luis (Chief Scientific Officer) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Exercised 7,452 options to buy
@ $1.03, valued at
$7.7k
|
|
| 03/23/2023 |
4
| Borges Luis (Chief Scientific Officer) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Sold 63,616 shares
@ $3.7706, valued at
$239.9k
Sold 65,698 shares
@ $3.7237, valued at
$244.6k
Sold 15,597 shares
@ $3.55, valued at
$55.4k
Exercised 63,616 options to buy
@ $1.03, valued at
$65.5k
Exercised 65,698 options to buy
@ $1.03, valued at
$67.7k
Exercised 220,930 options to buy
@ $1.03, valued at
$227.6k
|
|
| 03/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/22/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/20/2023 |
8-K
| Quarterly results |
| 03/17/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/16/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/09/2023 |
SC 13G/A
| Versant Venture Capital VI, L.P. reports a 19.4% stake in Century Therapeutics, Inc. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/06/2023 |
4
| Flores Osvaldo (CEO) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Granted 637,500 options to buy
@ $4.64, valued at
$3M
|
|
|